Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.33 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | CCR1 | P32246 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2439123 | 0.77 | — | — | |
| SCHEMBL31001732 | 0.77 | — | — | |
| Benzene SCHEMBL28857433 | 0.76 | PDE3B (0.34) | PDE3BPDE3AKDM4EMAPTGMNN | |
| Hydrochloric Acid SCHEMBL28075122 | 0.76 | PDE3B (0.34) | PDE3BPDE3AKDM4EMAPTGMNN | |
| Hydrochloric Acid SCHEMBL28108450 | 0.74 | PDE3B (0.33) | PDE3BPDE3AKDM4EMAPTGMNN | |
| SCHEMBL2120995 | 0.71 | — | — | |
| SCHEMBL2253282 | 0.69 | MAPT (0.48) | KDM4EMAPTLMNAHSP90AA1CYP3A4 | |
| SCHEMBL497374 | 0.68 | NOS3 (0.43) | MAPTLMNACYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL29369520 | 0.68 | NOS3 (0.43) | MAPTLMNACYP3A4TSHRSMN1; SMN2 | |
| SCHEMBL6397093 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108602823-A | As deubiquitinating enzymes（DUB）The spiral shell of inhibitor-condensation pyrrolidin derivatives | 特殊治疗有限公司 | 2018-09-28 | — | — | CN | claimed |
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | claimed |
| CN-116478130-B | N-hydroxyquinoline carboxamide compounds and uses thereof | 深圳默元生物科技有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4506035-A2 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| EP-3768668-B1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240122925-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | RELAY THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| CN-114539286-B | Piperazine derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-112166110-B | SHP2 phosphatase inhibitors and methods of use thereof | 传达治疗有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-114539286-A | Piperazine derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2022-05-27 | — | — | CN | disclosed |
| CN-108602823-A | As deubiquitinating enzymes（DUB）The spiral shell of inhibitor-condensation pyrrolidin derivatives | 特殊治疗有限公司 | 2018-09-28 | — | — | CN | disclosed |
| CN-105025899-B | Having a2AHeterobicyclically substituted- [1,2,4 ] antagonists]Triazolo [1,5-c]Quinazoline-5-amine compounds | 默沙东公司 | 2017-08-18 | — | — | CN | disclosed |
| EP-1761515-B1 | 2-(HETERO-)ARYL SUBSTITUTED TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-11-05 | — | — | EP | disclosed |
| CN-1067686-C | Fused polycyclic heterocycle derivatives | EISAI CO LTD (JP) | 2001-06-27 | — | — | CN | disclosed |
| CN-1185781-A | Fused Polycyclic Heterocyclic Derivatives | EISAI CO LTD (JP) | 1998-06-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240122925-A1 | SHP2 PHOSPHATASE INHIBITORS AND METHODS OF MAKING AND USING THE SAME | PTPN1, PTPN18, PTPN5 | CYP19A1 4471/4885TBXAS1 2365/4885PDE3B 1608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.